Clinical trial · no report yet · Phase 2
MONARCH 1
A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread
- NCT02102490 ↗
- Completed
- Eli Lilly and Company
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| Podcasts | 3 | |
| YouTube | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Metastatic Breast Cancer
- Interventions
- Abemaciclib
- Arms
- Abemaciclib · Experimental
- Enrollment
- 132
- Primary outcomes
- Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR])
- Sponsor
- Eli Lilly and Company
- Start
- Jun 10, 2014
- Primary completion
- Apr 30, 2016
- Results posted
- Yes
- Registry record
- NCT02102490 · updated Jan 21, 2020
Publications
linked from the registry- Dickler MN, Tolaney SM, Rugo HS, Cortes J, Dieras V, Patt D, Wildiers H, Hudis CA, O'Shaughnessy J, Zamora E, Yardley DA, Frenzel M, Koustenis A, Baselga J. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer. Clin Cancer Res. 2017 Sep 1;23(17):5218-5224. doi: 10.1158/1078-0432.CCR-17-0754. Epub 2017 May 22. PubMed 28533223